Becton Dickinson Q1 revenue beats on Connected Care segment strength

Becton Dickinson and

09/02/2026 11:39

Overview

Medical technology firm's Q1 revenue rose 1.6%, beating analyst expectations

Adjusted EPS for Q1 beat analyst estimates

Company to complete combination of Biosciences and Diagnostic Solutions with Waters Corp

Outlook

BD affirms FY26 revenue growth guidance for New BD as low single-digit plus

New BD FY26 adjusted diluted EPS expected between $12.35 and $12.65

Result Drivers

CONNECTED CARE GROWTH - Revenue in the Connected Care segment grew 5.5%, driven by advancements in medication management and patient monitoring systems

INTERVENTIONAL SEGMENT - The Interventional segment saw a 5.8% revenue increase, supported by new product clearances and portfolio expansions

BIOPHARMA INVESTMENT - $110 mln investment in U.S. pharmaceutical supply chain to expand syringe production and support biologic drug delivery

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$5.25 bln
$5.15 bln (9 Analysts)
Q1 Adjusted EPS
Beat
$2.91
$2.81 (10 Analysts)
Q1 EPS
$1.34


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Becton Dickinson and Co is $210.00, about 0% above its February 6 closing price of $210.02

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release: ID:nPn7hmDZMa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)